Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 DeFi Kingdoms DeFi Kingdoms +1,091.73%
#4 Black Phoenix Black Phoenix +335.28%
#5 aPriori aPriori +117.10%
#6 Bedrock Bedrock +74.91%
#7 Cysic Cysic +46.36%
#8 Prom Prom +40.32%
#9 Playnance Playnance +34.44%
#10 COTI COTI +33.90%
Coin of the day
Wrapped One Wrapped One
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Omnimmune Holdings, Inc. Omnimmune Holdings, Inc.

Omnimmune Holdings, Inc.

OMMH
Rang in Aktien #42527
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as... Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-07-17
Marktkapitalisierung
$981.00
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Omnimmune Holdings, Inc. (OMMH)

Kategorie

Healthcare
P/B-Verhältnis für Omnimmune Holdings, Inc. (OMMH)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Omnimmune Holdings, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Omnimmune Holdings, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR